Contact usContact us

The Company

Domain Therapeutics, a strategic partner of pharmaceutical companies, is aimed at discovering new drug candidates targeting G-Protein Coupled Receptors (GPCRs) in all major therapeutic fields.
GPCRs, by representing one third of current drug's targets, consitute one of the most validated therapeutic target classes. Whereas current GPCR drugs target about 50 receptors, there remains an untapped potential of approximately 350 GPCRs to be further investigated. These 350 members contain validated targets as well as orphan receptors.
Domain Therapeutics operates its GPCR-dedicated platforms to run drug discovery programs from hit generation to preclinical candidates and offers its partners to collaborate on drug discovery projects or to license patented drug candidates.
To date, Domain Therapeutics has signed research and/or collaboration agreements with: Takeda, Merck Serono, Prexton Therapeutics and ONO Pharmaceutical. The Company has generated programs in a wide range of major therapeutic fields including neurological, neuropsychiatric diseases, metabolic disorders, inflammation and oncology.

Domain Therapeutics
Last News

MAY 27, 2014

Domain Therapeutics appoints Dr Youssef L. Bennani as chairman of the board

Download the PDF file to learn more  

APRIL 14, 2014

Domain Therapeutics Continues Program to Alter Course of Parkinson’s Disease with Renewed Support of The Michael J. Fox Foundation

Download the PDF file to learn more  

FEBRUARY 4, 2014

Domain Therapeutics enters into collaboration with XOMA

Download the PDF file to learn more  

JANUARY 30, 2014

Pascal Neuville presents Domain Therapeutics activities to the President François Hollande during his official visit in Strasbourg